As reduction of CD206+ M2-like macrophages did not affect systemic adiposity, CD206+ M2-like ATMs-targeting drugs would not promote obesity, as is observed in the case of PPARγ activators (e.g. thiazolidinedione). The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.